Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bmcl.2021.128052 http://scihub22266oqcxt.onion/10.1016/j.bmcl.2021.128052 33887440!8055493!33887440     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Bioorg+Med+Chem+Lett 2021 ; 43 (ä): 128052 Nephropedia Template TP {{tp|p=33887440|t=2021. Development of ciclesonide analogues that block SARS-CoV-2 RNA replication |pdf=|usr=}}{{33887440}} gab.com Text Development of ciclesonide analogues that block SARS-CoV-2 RNA replication JO: Bioorg Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=33887440 #FOAvip Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). These compounds are promising as novel therapeutic agents for COVID-19 that show significant antiviral activity. Twit Text FOAVip Development of ciclesonide analogues that block SARS-CoV-2 RNA replication ????Bioorg Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=33887440 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33887440 #FOAvip English Wikipedia <ref>{{Cite pmid|33887440}}</ref> Development of ciclesonide analogues that block SARS-CoV-2 RNA replication #MMPMID33887440 Tsuji G; Yonemitsu K; Ito T; Yanase Y; Uema M; Ohoka N; Inoue T; Asakura H; Demizu Y Bioorg Med Chem Lett 2021[Jul]; 43 (ä): 128052 PMID33887440show ga Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). These compounds are promising as novel therapeutic agents for COVID-19 that show significant antiviral activity. |*COVID-19 Drug Treatment[MESH] |COVID-19/virology[MESH] |Glucocorticoids/pharmacology[MESH] |Humans[MESH] |Pregnenediones/*pharmacology[MESH] |RNA, Viral/*antagonists & inhibitors/genetics[MESH] |SARS-CoV-2/*drug effects/genetics[MESH]Development of ciclesonide analogues that block SARS-CoV-2 RNA replica(epmc).pdf DeepDyve Pubget Overpricing